List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 33 studies with search of:   "Angiopeptin"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Not yet recruiting An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Condition: Carcinoid Syndrome
Interventions: Drug: lanreotide;   Drug: placebo
2 Recruiting GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
Condition: Advanced Hepatocellular Carcinoma
Interventions: Drug: Octreotide-LAR, Lanreotide Autogel;   Drug: Octreotide-LAR or Lanreotide Autogel;   Other: Locoregional treatments
3 Completed Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Condition: Acromegaly
Interventions: Drug: Somatuline Autogel (lanreotide acetate);   Behavioral: Home administration
4 Recruiting Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer
Condition: Lymphocele
Interventions: Drug: Lanreotide LP 90;   Drug: Placebo lanreotide
5 Completed Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
Condition: Acromegaly
Intervention: Drug: Lanreotide-Autogel 120 mg
6 Recruiting Treatment of the Dumping Syndrome With Lanreotide Autogel®
Condition: Dumping Syndrome
Intervention: Drug: Somatuline (Lanreotide Autogel®)
7 Withdrawn Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
Condition: Acromegaly
Intervention: Drug: lanreotide (Autogel formulation)
8 Active, not recruiting Lanreotide as Treatment of Polycystic Livers
Conditions: Polycystic Liver Disease;   Hepatomegaly;   Liver Diseases;   Polycystic Kidney, Autosomal Dominant
Interventions: Drug: Placebo;   Drug: Lanreotide
9 Completed Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
Condition: Acromegaly
Intervention: Drug: Lanreotide Autogel and Octreotide LAR
10 Completed Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
Condition: Acromegaly
Interventions: Drug: Octreotide-LAR or lanreotide;   Procedure: Transsphenoidal adenomectomy
11 Terminated Lanreotide (Somatuline Autogel) in Thyroid-Associated Ophthalmopathy Treatment
Condition: Thyroid-Associated Ophthalmopathy
Intervention: Drug: Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
12 Active, not recruiting Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
Condition: Acromegaly
Interventions: Drug: lanreotide (Autogel formulation);   Drug: Pegvisomant
13 Completed Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: Lanreotide (Autogel formulation)
14 Completed Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
15 Recruiting Somatuline Autogel Preference and Health Economy Study
Condition: Neuroendocrine Tumour With Carcinoid Symptoms
Intervention: Drug: Lanreotide Autogel
16 Recruiting Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Condition: Acromegaly Associated With Pituitary Gland Macroadenoma
Intervention: Drug: Lanreotide autogel
17 Completed Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Condition: Acromegaly
Intervention: Drug: Lanreotide (Autogel formulation)
18 Completed Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae
Condition: Digestive Fistulae
Interventions: Drug: Lanreotide microparticles;   Drug: Placebo
19 Active, not recruiting Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Conditions: Intestinal Obstruction;   Carcinoma;   Peritoneal Neoplasms
Interventions: Drug: Lanreotide (microparticle formulation);   Other: Placebo
20 Completed Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
Condition: Acromegaly
Intervention: Drug: Lanreotide (Autogel formulation)

Previous Page Studies Shown (1-20) Next (21-33)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services